Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 16Colorectal Neoplasms 7Small Cell Lung Carcinoma 4Neoplasm Metastasis 4Stomach Neoplasms 3Recurrence 3Biliary Tract Neoplasms 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Triple Negative Breast Neoplasms 1Somatostatinoma 1Solid Tumor 1Small Cell Lung Cancer Extensive Stage 1Small Bowel Adenocarcinoma 1Rectal Neoplasms 1Rectal Cancer Patients 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Cancer Non-resectable 1Pancreatic Cancer Metastatic to Liver 1Pancreatic Adenocarcinoma 1PDAC - Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Neoplasms 1Neoadjuvant Chemotherapy 1Metastatic Pancreatic Adenocarcinoma 1Locally Advanced Rectal Cancer (LARC) 1

Interventions

Gemcitabine 2tremelimumab 1irinotecan sucrosofate 1durvalumab 1Taxes 1Oxaliplatin 1Medical Marijuana 1Leucovorin 1Fluorouracil 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Cancer Non-resectable × irinotecan sucrosofate × Clear all
NCT05047991 2021-09-17

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2 Unknown
153 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡